Clinical Trial

Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

Study acronym: INDIE
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 26, 2024 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-04-06; most recent amendment 2024-07-25.
Status change: Not Yet Recruiting → Recruiting 2024-07-25
Trial Details
NCT Number NCT04837859
Lead Sponsor University of Cologne
Conditions Classical Hodgkin Lymphoma
Enrollment 120 participants
Start Date 2024-05-24
Primary Completion 2026-05 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2024-07-26